Skip to Content

LK17-02

Main Content

Allogeneic hematopoietic transplant outcomes in adult patients with MLL-rearranged acute myeloid leukemia.

Study #: LK17-02

Study Status: Published

Presentation(s)

2020, TCT Meetings (Oral)

Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.

Citation

Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang M-J, Bo-Subait K, Sanchez J, Wang H-L, Aljurf M, Assal A, Bacher VU, Badawy SM, Bejanyan N, Bhatt VR, Bredeson CN, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla S, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt G, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus H, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson R, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan C, Sandmaier B, Litzow M, Kebriaei P, Weisdorf D, Zhang Y, Tallman MS, Saber W.

Blood Advances. 2022, Jan 08: 6(3): 6(3):828-847. doi: 10.1182/bloodadvances.2021004881. Epub 2021, Sep 22. PMCID:PMC8945306.

PubMed

PMID: 34551064

Abstract